BUILDING INDIGENOUS DIAGNOSTIC CAPABILITIES
India is facing a bigger burden of not having enough diagnostic kits in hand. Specifically, there is a shortage of reagents and consumables required to carry out the diagnostic tests for COVID-19. In order to overcome this burden, India is reaching out to South Korea, USA, Germany and China to arrange for more kits in order to increase the current testing capacity for COVID-19. Although this step might help India to some extent in its current containment plan, the real need can only be fulfilled by accelerating indigenous COVID-19 diagnostics manufacturing.
The BioSpectrum India edition was launched in March 2003 and is India's first comprehensive biotech business monthly magazine. It provides comprehensive coverage of the exciting happenings in life sciences, which include BioPharma, BioAgriculture, BioInformatics, BioIndustrial, BioSuppliers and BioServices and show cases the emerging Indian entrepreneurships in biotech industry. In a short time BioSpectrum has emerged as the most preferred platform to engage the life sciences industry in India and Asia Pacific. It is also widely accepted by research and academia community. Top key policy makers in the Central and state government use the magazine as a platform to reach out the Indian Biotech Industry. BioSpectrum has columns by Indian's top policy makers, biotechnology professionals, scientists and NGOs. Readers of BioSpectrum are from among the key Policy Makers, Key Executives and the Influencer's in Biotechnology, Pharmaceutical Companies, Research Heads of Clinical Research, Clinical Trials and Contract Mfg Organizations, Educational Institutes, Consultants, Fund Managers etc
